January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
What We're Reading: Trump Would Expand Insurance Coverage Through Medicaid
September 16th 2016What we're reading, September 16, 2016: Donald Trump mentions using Medicaid to expand coverage and making birth control available without a prescription; medical marijuana could curb the opioid epidemic; and how rare diseases are becoming more common.
Read More
Non-Orphan Use of Orphan Drugs Drives Up Cost
August 18th 2016The use of orphan drugs for non-orphan diseases is driving up the cost of these already expensive medications. A new report from America’s Health Insurance Plans found that almost half of the utilization for 46 orphan drugs were used for non-orphan indications.
Read More
Significant Toxicity of Mitoxantrone in Patients With Multiple Sclerosis: Cancer
May 13th 2016Researchers in Germany have discovered that mitoxantrone-used to treat aggressive, relapsing, or progressive multiple sclerosis-can increase the risk of leukemia and colorectal cancer in those being treated.
Read More
BCL-2 Inhibitor Venetoclax Approved as Second Line for CLL With 17p Deletion
April 11th 2016The approval comes following the review of a phase 2 single-arm trial in 106 patients with chronic lymphocytic leukemia who carried the 17p deletion mutation and who had received at least 1 prior therapy for their condition.
Read More
The authors review published evidence regarding associations between high cost sharing for specialty pharmaceuticals indicated for rheumatoid arthritis, multiple sclerosis, and cancer, and their utilization.
Read More